Sentiment-Signal
15,2
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Unternehmen & Branche
| Name | PROKIDNEY CORP. |
|---|---|
| Ticker | PROK |
| CIK | 0001850270 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 525,5 Mio. USD |
| Beta | 1,86 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -68,986,000 | 335,574,000 | -1,011,197,000 | ||
| 2025-09-30 | 10-Q | -16,469,000 | 351,608,000 | -1,008,020,000 | ||
| 2025-06-30 | 10-Q | -16,552,000 | 372,133,000 | -1,002,500,000 | ||
| 2025-03-31 | 10-Q | -16,734,000 | 406,061,000 | -998,553,000 | ||
| 2024-12-31 | 10-K | -61,186,000 | 441,073,000 | -994,954,000 | ||
| 2024-09-30 | 10-Q | -17,910,000 | 474,793,000 | -979,712,000 | ||
| 2024-06-30 | 10-Q | -12,506,000 | 499,163,000 | -972,371,000 | ||
| 2024-03-31 | 10-Q | -9,492,000 | 387,763,000 | -1,096,062,000 | ||
| 2023-12-31 | 10-K | -35,468,000 | 420,552,000 | -1,103,396,000 | ||
| 2023-09-30 | 10-Q | -10,984,000 | 451,806,000 | -1,092,637,000 | ||
| 2023-06-30 | 10-Q | -9,118,000 | 484,221,000 | -1,322,254,000 | ||
| 2023-03-31 | 10-Q | -9,665,000 | 495,151,000 | -1,601,510,000 | ||
| 2022-12-31 | 10-K | -54,503,000 | -0.23 | 517,996,000 | -1,096,616,000 | |
| 2022-09-30 | 10-Q | -29,930,000 | 532,438,000 | -1,096,325,000 | ||
| 2022-06-30 | 10-Q | -2,270,014 | 251,003,391 | 6,537,000 | ||
| 2022-03-31 | 10-Q | -3,981,025 | 250,752,227 | 20,167,000 | ||
| 2021-12-31 | 10-K | -2,324,629 | 40,298,000 | 26,917,000 | ||
| 2021-09-30 | 10-Q | -252,490 | 251,442,657 | 10,412,000 | ||
| 2021-06-30 | 10-Q | -143 | 622,804 | 15,880,000 | ||
| 2021-03-31 | 10-Q | -5,182 | 19,818 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.